Spyre Therapeutics (SYRE) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Strategic vision and innovation

• Aims to develop next-generation antibody therapies for inflammatory bowel disease (IBD) by improving both efficacy and dosing convenience, targeting quarterly or even twice-annual dosing.

• Focuses on three targets: alpha-4 beta-7, TL1A, and IL-23, chosen for their efficacy and favorable safety profiles without black box warnings.

• Plans to test these agents in combination, leveraging proof-of-concept data suggesting combinations can break through the traditional efficacy ceiling in IBD.

• Utilizes half-life extending modifications to enable less frequent dosing and potentially greater patient convenience.

• Emphasizes the importance of safety in combination therapies, particularly with gut-selective mechanisms to minimize immunosuppressive risk.

Clinical and preclinical data highlights

• Phase I data for Spy1 (alpha-4 beta-7) showed a half-life exceeding 90–100 days, supporting quarterly or even twice-annual dosing.

• Safety profile in early studies was unremarkable, with complete target saturation and no significant immunogenicity concerns anticipated.

• Higher drug exposure correlates with increased clinical remission rates, and plans are in place to test higher doses for improved efficacy.

• Preclinical and animal models support additive or synergistic efficacy for all three target combinations.

• TL1A and IL-23 candidates show promising potency and half-life in non-human primates, with Phase I data expected in the first and second halves of next year, respectively.

Competitive landscape and industry context

• Combination therapy momentum is driven by the Vega study, which showed nearly double remission rates with combination versus monotherapy.

• Other companies (e.g., Prometheus, Pfizer, Roivant) are advancing TL1A programs, but the presented molecules aim for superior potency and half-life.

• The Duet studies, expected to read out next year, will further inform the field on combination efficacy in refractory IBD patients.

• The platform study will include both naive and refractory patients, with a design allowing staggered initiation of different arms as data become available.

• Co-formulated products are expected to be priced similarly to single agents, supporting broader adoption if efficacy and safety are favorable.